Major investment by Astrazeneca

A new 255 million Euro high-tech facility for the manufacture of biological medicines is to be built in Södertälje. The new plant will focus on the filling and packaging of protein therapeutics. AstraZeneca’s largest global tablets and capsules manufacturing facility and launch platform site is also located in Södertälje. By locating the new manufacturing plant in Södertälje, the company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden Operations unit.

Pascal Soriot, Chief Executive Officer, AstraZeneca